Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008

Overview

Journal Obstet Gynecol

Specialty Gynecology & Obstetrics

Date 2015 Dec 10

PMID 26646132

Citations 16

Authors

Jenny J Lin

Natalia Egorova

Rebeca Franco

Monica Prasad-Hayes

Nina A Bickell

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate whether overall survival is improving among women in the United States with advanced ovarian cancer.

Methods: This retrospective cohort study evaluated trends in treatment and overall survival for women older than 65 years diagnosed with stage III and IV epithelial ovarian cancer between 1995 and 2008 using Surveillance, Epidemiology, and End Results-Medicare data. Parametric and semiparametric multivariate survival analyses were used to assess comparative treatment survival rates and factors affecting survival and recurrence.

Results: Of 7,938 women who met study criteria, 2.9% received no treatment, 15.4% underwent surgery only, 24.8% received chemotherapy only, 41.8% underwent primary debulking surgery and chemotherapy in an optimal timeframe, and 15.1% had primary debulking surgery and chemotherapy, but the timing was not optimal or patients did not complete all six cycles of chemotherapy. Those who underwent surgery only had similar survival as those who received no treatment (2.2 compared with 1.7 months), whereas those who received chemotherapy only had a better overall survival (14.4 months). Optimal treatment was associated with the longest survival time (P<.001, median overall survival 39.0 months). Additionally, survival time associated with optimal treatment increased over the past decade. However, the proportion of women who received optimal treatment has decreased over the past decade.

Conclusion: Elderly women with advanced ovarian cancer have the best survival with optimal therapy. When this is not offered or possible, chemotherapy alone offers better survival than surgery alone.

Citing Articles

Effectiveness and safety of standard chemotherapy in older patients with ovarian cancer: a retrospective analysis by age group and treatment regimen.

Brezis M, Shachar E, Peleg Hasson S, Laskov I, Michaan N, Levy B Front Oncol. 2023; 13:1289379.

PMID: 38152363 PMC: 10751294. DOI: 10.3389/fonc.2023.1289379.

ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE.

Guruvaiah P, Chava S, Sun C, Singh N, Penn C, Gupta R Cell Death Dis. 2023; 14(7):456.

PMID: 37479754 PMC: 10362061. DOI: 10.1038/s41419-023-05993-9.

Do ethnic chinese older adults with epithelial ovarian cancer survive a poorer prognosis?.

Huang W, Bao Y, Luo X, Yao L, Yuan L J Ovarian Res. 2023; 16(1):110.

PMID: 37277766 PMC: 10242771. DOI: 10.1186/s13048-023-01177-3.

The Potential of Novel Lipid Agents for the Treatment of Chemotherapy-Resistant Human Epithelial Ovarian Cancer.

Nachtigal M, Altman A, Arora R, Schweizer F, Arthur G Cancers (Basel). 2022; 14(14).

PMID: 35884379 PMC: 9322924. DOI: 10.3390/cancers14143318.

Frailty repels the knife: The impact of frailty index on surgical intervention and outcomes.

Handley K, Sood A, Molin G, Westin S, Meyer L, Fellman B Gynecol Oncol. 2022; 166(1):50-56.

PMID: 35599168 PMC: 11847601. DOI: 10.1016/j.ygyno.2022.05.009.

References

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

van der Burg M, van Lent M, Buyse M, Kobierska A, Colombo N, Favalli G . The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. N Engl J Med. 1995; 332(10):629-34. DOI: 10.1056/NEJM199503093321002. View

Bristow R, Montz F, Lagasse L, Leuchter R, Karlan B . Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999; 72(3):278-87. DOI: 10.1006/gyno.1998.5145. View

Goff B, Matthews B, Wynn M, Muntz H, Lishner D, Baldwin L . Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol. 2006; 103(2):383-90. DOI: 10.1016/j.ygyno.2006.08.010. View

Patankar S, Burke W, Hou J, Tergas A, Huang Y, Ananth C . Risk stratification and outcomes of women undergoing surgery for ovarian cancer. Gynecol Oncol. 2015; 138(1):62-9. PMC: 4469531. DOI: 10.1016/j.ygyno.2015.04.037. View

Bristow R, Chang J, Ziogas A, Randall L, Anton-Culver H . High-volume ovarian cancer care: survival impact and disparities in access for advanced-stage disease. Gynecol Oncol. 2013; 132(2):403-10. DOI: 10.1016/j.ygyno.2013.12.017. View

Fader A, Rose P . Role of surgery in ovarian carcinoma. J Clin Oncol. 2007; 25(20):2873-83. DOI: 10.1200/JCO.2007.11.0932. View

Chi D, Zivanovic O, Levinson K, Kolev V, Huh J, Dottino J . The incidence of major complications after the performance of extensive upper abdominal surgical procedures during primary cytoreduction of advanced ovarian, tubal, and peritoneal carcinomas. Gynecol Oncol. 2010; 119(1):38-42. DOI: 10.1016/j.ygyno.2010.05.031. View

Guidozzi F, BALL J . Extensive primary cytoreductive surgery for advanced epithelial ovarian cancer. Gynecol Oncol. 1994; 53(3):326-30. DOI: 10.1006/gyno.1994.1142. View

10.

Kuo T, Mobley L, Bazzoli G . Changes in the health care safety net 1992-2003: disparities in access for uninsured persons in Florida. Int J Health Serv. 2013; 43(3):551-66. PMC: 3785010. DOI: 10.2190/HS.43.3.k. View

11.

Ledermann J, Raja F, Fotopoulou C, Gonzalez-Martin A, Colombo N, Sessa C . Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013; 24 Suppl 6:vi24-32. DOI: 10.1093/annonc/mdt333. View

12.

Fairfield K, Lucas F, Earle C, Small L, Trimble E, Warren J . Regional variation in cancer-directed surgery and mortality among women with epithelial ovarian cancer in the Medicare population. Cancer. 2010; 116(20):4840-8. DOI: 10.1002/cncr.25242. View

13.

van Walraven C, Austin P, Jennings A, Quan H, Forster A . A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data. Med Care. 2009; 47(6):626-33. DOI: 10.1097/MLR.0b013e31819432e5. View

14.

Bristow R, Tomacruz R, Armstrong D, Trimble E, Montz F . Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002; 20(5):1248-59. DOI: 10.1200/JCO.2002.20.5.1248. View

15.

Van Altena A, Karim-Kos H, de Vries E, Kruitwagen R, Massuger L, Kiemeney L . Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands. Gynecol Oncol. 2012; 125(3):649-54. DOI: 10.1016/j.ygyno.2012.02.033. View

16.

Pujade-Lauraine E . How to approach patients in relapse. Ann Oncol. 2012; 23 Suppl 10:x128-31. DOI: 10.1093/annonc/mds358. View

17.

Vergote I, Trope C, Amant F, Kristensen G, Ehlen T, Johnson N . Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010; 363(10):943-53. DOI: 10.1056/NEJMoa0908806. View

18.

Gerestein C, Nieuwenhuyzen-de Boer G, Eijkemans M, Kooi G, Burger C . Prediction of 30-day morbidity after primary cytoreductive surgery for advanced stage ovarian cancer. Eur J Cancer. 2009; 46(1):102-9. DOI: 10.1016/j.ejca.2009.10.017. View

19.

Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun M . Cancer statistics, 2009. CA Cancer J Clin. 2009; 59(4):225-49. DOI: 10.3322/caac.20006. View

20.

Warren J, Klabunde C, Schrag D, Bach P, Riley G . Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population. Med Care. 2002; 40(8 Suppl):IV-3-18. DOI: 10.1097/01.MLR.0000020942.47004.03. View